BioMed Valley Discoveries, Inc.
- Biotech or pharma, therapeutic R&D
Biomed Valley Discoveries (BVD) pipeline includes three assets: [1] a clinical stage best-in-class selective ERKi (ulixertinib) delivered orally as a mono therapy and in combination, [2] a clinical stage attenuated anaerobe bacteria (CNV-NT) delivered intratumorally for direct tumor killing and immune-stimulation, and [3] a preclinical stage antibody (TEM8) targeting the tumor microenvironment as an Antibody Drug Conjugate. BVD is actively seeking licensing/collaboration of CNV-NT, and is scheduling discussions on ulixertinib and TEM8 for near-term transactions.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}